Short Interest in Orion OYJ Unsponsored ADR (OTCMKTS:ORINY) Declines By 86.2%

Key Points

• Short interest in Orion OYJ Unsponsored ADR decreased by 86.2%, falling to 400 shares as of August 15th.
• The stock price of Orion OYJ was trading at $38.35, with a market cap of $10.83 billion and a PE ratio of 26.09.
• For the recently reported quarter, Orion OYJ posted an EPS of $0.33 and revenue of $472.57 million, with a net margin of 22.61%.

Orion OYJ Unsponsored ADR (OTCMKTS:ORINY - Get Free Report) was the recipient of a large decrease in short interest during the month of August. As of August 15th, there was short interest totaling 400 shares, adecreaseof86.2% from the July 31st total of 2,900 shares. Based on an average daily volume of 400 shares, the days-to-cover ratio is currently 1.0 days. Based on an average daily volume of 400 shares, the days-to-cover ratio is currently 1.0 days.

Orion OYJ Stock Performance

ORINY stock traded down $1.34 on Tuesday, hitting $38.35. The company's stock had a trading volume of 1,127 shares, compared to its average volume of 168. The firm has a 50 day moving average of $39.19 and a two-hundred day moving average of $33.73. Orion OYJ has a 1 year low of $21.95 and a 1 year high of $41.60. The stock has a market cap of $10.83 billion, a price-to-earnings ratio of 26.09 and a beta of 0.11. The company has a current ratio of 1.86, a quick ratio of 1.05 and a debt-to-equity ratio of 0.15.

Orion OYJ (OTCMKTS:ORINY - Get Free Report) last released its quarterly earnings results on Friday, July 18th. The company reported $0.33 EPS for the quarter. Orion OYJ had a net margin of 22.61% and a return on equity of 38.68%. The firm had revenue of $472.57 million during the quarter. Equities analysts predict that Orion OYJ will post 1.18 EPS for the current fiscal year.

About Orion OYJ

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson's disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.